Evidence map›Paper›PMID 39905897›Full record

ArticleAdvanced healthcare materials2025

Glepaglutide-Loaded Foam for the Induction of Mucosal Healing in the Treatment of Inflammatory Bowel Disease.

Wunan Zhang, William Van den Bossche, Hafsa Yagoubi, Espoir K Kambale, Khadija Wahni, Tanya Saxena, Léo Guilbaud, Tom G Moreels, Joris Messens, Ana Beloqui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wunan ZhangUCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, 1200, Belgium.
William Van den BosscheUCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, 1200, Belgium.
Hafsa YagoubiUCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, 1200, Belgium.
Espoir K KambaleUCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, 1200, Belgium.
Khadija WahniVIB-VUB Center for Structural Biology, Brussels, 1050, Belgium.
Tanya SaxenaUCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, 1200, Belgium.
Léo GuilbaudUCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, 1200, Belgium.
Tom G MoreelsInstitute of Experimental and Clinical Research, Laboratory of Hepato-Gastroenterology, UCLouvain, Université Catholique de Louvain, Brussels, 1200, Belgium.
Joris MessensVIB-VUB Center for Structural Biology, Brussels, 1050, Belgium.
Ana BeloquiUCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, 1200, Belgium.ORCID 0000-0003-4221-3357

Funding

Fonds De La Recherche Scientifique - FNRS J.0010.20FRFS-WELBIOWallon region WELBIO-CR-2022 S-01
6 · The paper itself

Abstract

Glucagon-like peptide 2 (GLP-2) stimulates intestinal growth, repairs mucosa, and enhances epithelial integrity but has a short half-life (7 min). Glepaglutide (GL), a GLP-2 analog with an extended half-life (50 h), is currently undergoing clinical trials for patients with short bowel syndrome. GL requires subcutaneous injection, which poses challenges for potential patient compliance. To address this challenge, GL was loaded into a rectal foam formulation using CO

Indexed as

Anti-Inflammatory AgentsGlucagon-Like Peptide 2Inflammatory Bowel DiseasesIntestinal MucosaAnimalsDextran SulfateDisease Models, AnimalMaleMiceAnti-Inflammatory AgentsDextran SulfateglepaglutideGlucagon-Like Peptide 2colon deliveryfoamgas permeation enhancerglepaglutideinflammatory bowel disease

Identifiers

PMID39905897
PMCPMC11912111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.